194423-15-9PD1683931MG | >98%,c-Met和VEGFR-2YZ剂 |
928037-13-2Golvatinib (E7050) 5MG | >98%,选择性VEGFRYZ剂 |
194413-58-6Semaxanib (SU5416)5MG | >98%,选择性VEGFR2YZ剂 |
228559-41-9Ki87515MG | >98%,Met/VEGFR2YZ剂 |
1174046-72-0BMS-7948335MG | >98%,选择性PDGFRα/βYZ剂 |
343787-29-1CP-6734515MG | >98%,多靶点YZ剂 |
1092788-83-4PP12110MG | >98%,c-Kit, PDGFα和Flt3多靶点YZ剂 |
850879-09-3Amuvatinib (MP-470)5MG | >98%,c-Met(WT/mutants)多靶点YZ剂 |
917879-39-1MK-24615MG | >98%,Met相关的YZ剂 |
1025720-94-8BMS-7776075MG | >98%,EGFR, ErbB2 和ErbB3YZ剂 |
848942-61-0AZD8931 (Sapitinib)5MG | >98%,选择性HER2/ErbB2YZ剂 |
537705-08-1CP-724714 5MG | >98%,有效的HER2/ErbB2YZ剂 |
366017-09-6Mubritinib (TAK 165)10MG | >98%,选择性的IGF-1RYZ剂 |
867160-71-2OSI-906 (Linsitinib)5MG | >98%,Bcr-AblYZ剂 |
1020172-07-9DCC-2036 (Rebastinib)10MG | >98%,Bcr-AblYZ剂 |
778270-11-4GNF-2 5MG | >98%,Bcr-Abl |